Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT02985918 Terminated - Clinical trials for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

High-Intensity vs Low-Intensity NPPV in Patients With an AECOPD: The HAPPEN Trial

Start date: January 3, 2019
Phase: N/A
Study type: Interventional

To determine whether high-intensity NPPV, compared with low-intensity NPPV, could reduce the need for endotracheal intubation during hospitalization in patients with an AECOPD and hypercapnia.

NCT ID: NCT02978885 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Imaging of Peri-operative (periOP) Lung Injury

Start date: June 11, 2018
Phase: Phase 2
Study type: Interventional

The aim of study is to determine if 99mTc Annexin V-128 (AxV- 128/Tc) single photon emission computed tomography (SPECT)-computed tomography (CT) can detect perioperative lung injury. The investigators will study patients undergoing major surgery, specifically Whipple procedures (pancreatico-duodenectomies) and compare AxV-128/Tc SPECT-CT scans before and after surgery in Chronic Obstructive Pulmonary Disease (COPD) and non-COPD patients.

NCT ID: NCT02958917 Terminated - Clinical trials for Interstitial Lung Disease

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

Start date: June 5, 2017
Phase: Phase 2
Study type: Interventional

Patients are being offered participation in this pirfenidone trial because They have been diagnosed with fibrotic hypersensitivity pneumonitis (FHP), a type of interstitial lung disease (ILD). This is a disease where scarring of lung tissue occurs as the result of inhaling substances called antigens. These antigens can be substances such as molds, chemicals or dust. As a result of this scarring the lungs are is not able to move oxygen into the bloodstream to reach other organs. Currently over 1400 subjects have been treated with pirfenidone in 15 clinical trials. This drug has been approved by the Food and Drug Administration (FDA) for use in Idiopathic Pulmonary Fibrosis, a different type of ILD, but requires special permission for use in your condition. The use of pirfenidone has not been approved for the treatment of FHP. It is considered experimental treatment in this study.

NCT ID: NCT02950116 Terminated - Asthma Clinical Trials

Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease

Start date: March 9, 2017
Phase: N/A
Study type: Interventional

Chronic respiratory diseases (CRDs) affect the airways and other structures of the lungs and thereby lead to ventilation inhomogeneity. The most common CRDs in children are asthma, bronchiectasis and cystic fibrosis (CF). All three are obstructive diseases. However, while asthma is mostly characterized by obstruction due to bronchoconstriction of the airways, obstruction in bronchiectasis and CF originates primarily from mucus retention due to abnormal airway clearance mechanisms. The Nitrogen Multiple Breath Washout test (N2-MBW-test) is a robust and sensitive detector of early pulmonary changes and ventilation inhomogeneity. The minimal cooperation which is required for this test makes it very convenient for use in any age category. Research on LCI described it as a reliable indicator of obstructive lung disease in pediatric CF patients as from 6 years of age. Whether LCI is a reliable parameter for early lung disease in asthma children is less clearly demonstrated. No data were found on LCI calculated from the N2-MBW-test in children with bronchiectasis.

NCT ID: NCT02888730 Terminated - Cystic Fibrosis Clinical Trials

Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

AVASMUC
Start date: February 16, 2017
Phase: Phase 3
Study type: Interventional

Patients with cystic fibrosis frequently develop chronic rhinosinusitis. Bacterial colonization is facilitated by a reduced mucociliary function and some previous studies suggest that the microbiology of the upper airways might influence the microbiology of the lower airway. The aim of this randomized control study is to demonstrate efficacy of antibiotic delivered by nebulized sonic aerosol therapy to decrease the bacterial load in sinuses and medium ostia and to improve the sino-nasal symptoms and endoscopic scores, quality of life and lung function

NCT ID: NCT02888444 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Smoking Relapse Prevention Among COPD Ex-smokers

SPACE
Start date: July 31, 2017
Phase: Phase 3
Study type: Interventional

A placebo-controlled trial to determine whether recent ex-smokers with COPD who successfully stop smoking after taking varenicline are less likely to relapse back to smoking if they continue using varenicline for a further 12 weeks

NCT ID: NCT02877641 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Start date: April 16, 2014
Phase: Phase 2
Study type: Interventional

This phase IIb randomized trial studies how well cholecalciferol (vitamin D3) supplementation works in strengthening inspiratory muscles in cholecalciferol-deficient patients with chronic obstructive pulmonary disease (COPD). Cholecalciferol supplementation may help reduce the risk of developing lung cancer and strengthen the diaphragm in cholecalciferol-deficient patients with COPD.

NCT ID: NCT02825043 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

HFNC Effect on BCSS in Patients With COPD

COPD
Start date: February 2016
Phase: N/A
Study type: Interventional

The primary objective of this study is to look for a correlation between the use of high-flow nasal cannula in the outpatient setting in patients with previous chronic obstructive pulmonary disease exacerbation and the change in their Breathlessness, Cough, and Sputum Scale score. The hypothesis is that home use of high-flow nasal cannula will lead to a reduction in Breathlessness, Cough, and Sputum Scale score by 1.3.

NCT ID: NCT02813447 Terminated - Depression Clinical Trials

Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)

SAD-COPD
Start date: August 2016
Phase: N/A
Study type: Interventional

Objective: Determine whether treatment of perceived stress, anxiety, and depression with anti-depressant therapy improves dyspnea scores, 6-minute walk (6MW) distance and quality of life (QoL) in patients with Chronic Obstructive Pulmonary Disease (COPD) and ILD (Interstitial Lung Disease) undergoing pulmonary rehab. The study is a prospective, randomized, double-blinded, placebo-controlled study to assess the effect of an SSRI on 6MW, dyspnea scores, and QoL in COPD and ILD patients undergoing pulmonary rehab. Thirty subjects that carry an ICD-9 code diagnosis of COPD and/or ILD and CES-D (Center for Epidemiologic Studies Depression) score of > 16 will be recruited from Duke Pulmonary Rehab. Multivariable regression models will be constructed to evaluate the relationship between perceived stress, anxiety, and depression with adjustments by race, gender, age, BMI and GOLD score. A multivariable regression model will be constructed to assess whether treatment of perceived stress, depression, and anxiety with antidepressant therapy (sertraline) is an effect modifier on 6MW distance and dyspnea scores in patients with COPD or ILD who are enrolled in pulmonary rehab. Descriptive statistics will be used to examine the socio-demographic characteristic data. Student t-tests will be performed to assess group differences in continuous data. Categorical variables will be examined using the Pearson's Chi-Squared test.

NCT ID: NCT02805127 Terminated - Asthma Clinical Trials

Obstructive Airways Diseases in Emergency Department (OADED) Study

Start date: December 22, 2016
Phase: N/A
Study type: Observational

This is an observational study which aims to evaluate the possibility of using data from a capnography device to assess obstructive airway severity in both Chronic Obstructive Pulmonary Disease (COPD) and Asthma patients.